Last Price$201.09NASDAQ Previous Close - Last Trade as of 1:00PM ET 11/26/21

Today's Change0(0.00%)
Bid (Size)$201.20 (2)
Ask (Size)$202.29 (2)
Day Low / HighN/A - N/A
Volume3.2 M

View Biotechnology IndustryPeer Comparison as of 11/26/2021


Amgen Inc ( NASDAQ )

Price: $201.09
Change: -2.88 (1.41%)
Volume: 3.2 M
1:00PM ET 11/26/2021

Moderna Inc ( NASDAQ )

Price: $329.63
Change: +56.24 (20.57%)
Volume: 35.9 M
1:00PM ET 11/26/2021

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Gilead Sciences Inc ( NASDAQ )

Price: $70.27
Change: +0.20 (0.29%)
Volume: 5.7 M
1:00PM ET 11/26/2021

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $643.35
Change: -4.83 (0.75%)
Volume: 575.6 K
1:00PM ET 11/26/2021

Read more news Recent News

Mizuho Securities Cuts Amgen's Price Target to $194 From $222, Citing 'Potential 2022 Headwinds,' Says 'Valuations Could Be Even Lower;' Neutral Rating Kept
5:27AM ET 11/22/2021 MT Newswires

Amgen (AMGN) has an average rating of outperform and price targets ranging from $190 to $298, according to analysts polled by Capital IQ. (MT Newswires...

BMO Capital Starts Amgen at Market Perform With $228 Price Target
5:51AM ET 11/19/2021 MT Newswires

Amgen (AMGN) has an average rating of outperform and price targets ranging from $200 to $298, according to analysts polled by Capital IQ. (MT Newswires...

Amgen's KRAS G12C Inhibitor Recommended For Conditional Marketing Authorization For Advanced Non-Small-Cell Lung Cancer Treatment
11:02AM ET 11/12/2021 MT Newswires

Amgen (AMGN) said Friday the European Medicines Agency recommended conditional marketing authorization of the company's LUMYKRAS sotorasib inhibitor for...

Amgen Kicks off Construction of Biomanufacturing Plant With Plans to Invest $365 Million
4:10PM ET 11/05/2021 MT Newswires

Amgen (AMGN) on Friday announced the groundbreaking of its newest biomanufacturing plant in New Albany, Ohio. "In building this site, we expect to invest...

View all Commentary and Analysis

Ligand's (LGND) Drug-Developing Technologies Holds Potential
2:37PM ET 11/26/2021 Zacks

Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off...

Buy Alert: Don't Miss These 5 Blue Chip Black Friday Bargains
9:30AM ET 11/26/2021 Seeking Alpha

Nicholas Ward's Dividend Growth Portfolio: October 2021 Review
4:44AM ET 11/21/2021 Seeking Alpha

High Quality Dividend Growth Near 52-Week Lows: MarketAxess Merits Examination
2:48AM ET 11/20/2021 Seeking Alpha

Company Profile

Business DescriptionAmgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA. View company web site for more details
AddressOne Amgen Center Drive
Thousand Oaks, California 91320-1799
Number of Employees21,500
Recent SEC Filing11/09/20214
Chairman, President & Chief Executive OfficerRobert A. Bradway
Executive Vice President-OperationsEsteban Santos
Chief Financial Officer & Executive Vice PresidentPeter H. Griffith
Chief Information Officer & Senior Vice PresidentMike Zahigian

Company Highlights

Price Open$204.74
Previous Close$203.97
52 Week Range$200.47 - 276.69
Market Capitalization$113.3 B
Shares Outstanding563.3 M
SectorHealth Technology
Current Dividend / Yield$1.76 / 3.50%
Dividend Ex-Date11/15/2021
Dividend Pay-Date12/08/2021
Dividend Yield 5 Year Average2.66%
Next Earnings Announcement02/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings21.22
Earnings per Share$11.40
Beta vs. S&P 500N/A
Revenue$23.8 B
Net Profit Margin21.76%
Return on Equity63.73%

Analyst Ratings as of 11/19/2021

Consensus RecommendationConsensus Icon
Powered by Factset